Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent cytomegalovirus (CMV) disease in transplant recipients.
• Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients.
• Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

Activity Description

Cytomegalovirus (CMV) infection after solid organ and hematopoietic stem cell transplantation is one of the most critical infectious complications related to host immune recovery. Management of the virus is categorized into prophylactic, preemptive, and targeted treatment. Conventional anti-CMV therapies are associated with suboptimal efficacy, toxicity, and resistance. Newer antivirals may provide effective prevention as well as treatment of CMV disease without the safety concerns and drug resistance. In this continuing medical education activity, expert clinicians will discuss the latest on diagnosing and managing patients with CMV infection in the transplantation setting.

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Chief Infection Control Officer
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure:
Consulting Fee: Ansun BioPharma, Chimerix, Cidara, Janssen, Merck, Oxford Immunotec, ReViral, Takeda
Speakers Bureau: Merck
Contracted Research: AiCuris, Ansun BioPharma, Janssen, Karius, Merck, Takeda, Viracor

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, March 2, 2021 to March 1, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent cytomegalovirus (CMV) disease in transplant recipients.
• Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients.
• Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

Activity Description

Cytomegalovirus (CMV) infection after solid organ and hematopoietic stem cell transplantation is one of the most critical infectious complications related to host immune recovery. Management of the virus is categorized into prophylactic, preemptive, and targeted treatment. Conventional anti-CMV therapies are associated with suboptimal efficacy, toxicity, and resistance. Newer antivirals may provide effective prevention as well as treatment of CMV disease without the safety concerns and drug resistance. In this continuing medical education activity, expert clinicians will discuss the latest on diagnosing and managing patients with CMV infection in the transplantation setting.

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Chief Infection Control Officer
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure:
Consulting Fee: Ansun BioPharma, Chimerix, Cidara, Janssen, Merck, Oxford Immunotec, ReViral, Takeda
Speakers Bureau: Merck
Contracted Research: AiCuris, Ansun BioPharma, Janssen, Karius, Merck, Takeda, Viracor

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, March 2, 2021 to March 1, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

• Evaluate clinical trial results of frontline treatment options that are available for the treatment of patients with newly diagnosed MM
• Review maintenance therapy strategies for patients with MM that are eligible to receive this type of therapy
• Assess treatment approaches and sequencing of therapy for patients with relapsed and/or refractory MM
• Optimize approaches to manage treatment-related adverse events that may occur during the treatment of patients with MM
• Discuss clinical trials results that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will provide the most up-to-date information to clinicians treating patients with MM, strategies to evaluate best practices and emerging clinical data, and expert insights on how to apply them safely and effectively to your patients.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia

Pieter Sonneveld, MD, PhD
Professor of Hematology
Erasmus MC Cancer Institute/University Medical Center
Rotterdam, The Netherlands

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Sagar Lonial, MD, FACP
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Pieter Sonneveld, MD, PhD
Employment: Hematology, Erasmus MC Cancer Institute, Rotterdam
Discussion of off-label drug use: Not Applicable
Research support: Amgen Inc., Celgene Corporation, Janssen, Karyopharm Therapeutics, SkylineDx
Advisory Boards: Amgen Inc., BMS/Celgene, Janssen, Karyopharm Therapeutics, Oncopeptides, SkylineDx, Seattle Genetics

Chair European Myeloma Network
Chair Hovon Myeloma Working Group

Planning Committee
The following planning committee members have nothing to disclose:
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Oncopeptides.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

• Evaluate clinical trial results of frontline treatment options that are available for the treatment of patients with newly diagnosed MM
• Review maintenance therapy strategies for patients with MM that are eligible to receive this type of therapy
• Assess treatment approaches and sequencing of therapy for patients with relapsed and/or refractory MM
• Optimize approaches to manage treatment-related adverse events that may occur during the treatment of patients with MM
• Discuss clinical trials results that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will provide the most up-to-date information to clinicians treating patients with MM, strategies to evaluate best practices and emerging clinical data, and expert insights on how to apply them safely and effectively to your patients.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia

Pieter Sonneveld, MD, PhD
Professor of Hematology
Erasmus MC Cancer Institute/University Medical Center
Rotterdam, The Netherlands

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Sagar Lonial, MD, FACP
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Pieter Sonneveld, MD, PhD
Employment: Hematology, Erasmus MC Cancer Institute, Rotterdam
Discussion of off-label drug use: Not Applicable
Research support: Amgen Inc., Celgene Corporation, Janssen, Karyopharm Therapeutics, SkylineDx
Advisory Boards: Amgen Inc., BMS/Celgene, Janssen, Karyopharm Therapeutics, Oncopeptides, SkylineDx, Seattle Genetics

Chair European Myeloma Network
Chair Hovon Myeloma Working Group

Planning Committee
The following planning committee members have nothing to disclose:
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Oncopeptides.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

• Evaluate various frontline treatment options that are available for the treatment of patients with newly diagnosed MM
• Discuss maintenance therapy options that may be appropriate for patients with MM
• Assess strategies for proper sequencing of agents and regimens in patients with progressive disease
• Review common adverse events that are associated with various treatment strategies and approaches to mitigating such adverse events

Activity Description

This activity will provide expert guidance regarding the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents. It is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs.

Statement of Educational Need

Major advances in the diagnosis and treatment of MM have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients.

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia

Disclosures
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis.

Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

All disclosed conflicts of interest have been resolved by independent content review.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from GlaxoSmithKline, Janssen, and Oncopeptides.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

• Evaluate various frontline treatment options that are available for the treatment of patients with newly diagnosed MM
• Discuss maintenance therapy options that may be appropriate for patients with MM
• Assess strategies for proper sequencing of agents and regimens in patients with progressive disease
• Review common adverse events that are associated with various treatment strategies and approaches to mitigating such adverse events

Activity Description

This activity will provide expert guidance regarding the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents. It is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs.

Statement of Educational Need

Major advances in the diagnosis and treatment of MM have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients.

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia

Disclosures
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis.

Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

All disclosed conflicts of interest have been resolved by independent content review.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from GlaxoSmithKline, Janssen, and Oncopeptides.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.

Learning Objectives

After participating in this activity, participants should be better able to:

• Identify the role of BTK signaling in the pathogenesis of CLL, and the rationale for targeting BTK in patients with this malignancy
• Assess clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
• Evaluate emerging clinical trial data of current and novel BTK inhibitors, including monotherapy and combination approaches
• Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, as well as oral adherence strategies

Activity Description

Bruton’s tyrosine kinase (BTK) inhibitors are an evolving therapeutic strategy for the treatment of patients with CLL. With multiple BTK inhibitors (and combinations) under investigation and pending approval, clinicians need expert guidance to correctly use these agents safely and effectively for patients with CLL, and plan strategies for optimal integration of these novel agents into practice. This webcast will provide expert interpretation of emerging data and guidance regarding patient diagnosis, treatment, maintenance therapy, and sequencing of agents.

Statement of Educational Need

BTK inhibitors have substantially altered the management, clinical course, and outcome of patients with CLL. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Ibrutinib was the first orally available, nonselective and irreversible inhibitor of BTK approved for the treatment of patients with various B-cell malignancies. Newer and more selective BTK inhibitors are currently in clinical development, including acalabrutinib, which is currently US FDA approved for previously treated mantle cell lymphoma. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control.

Faculty

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical Center
Associate Director, Center for Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts

Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.

Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research to Practice, TG Therapeutics, Verastem, Inc.

Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

All disclosed conflicts of interest have been resolved by independent content review.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, BeiGene and Pharmacyclics.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.

Learning Objectives

After participating in this activity, participants should be better able to:

• Identify the role of BTK signaling in the pathogenesis of CLL, and the rationale for targeting BTK in patients with this malignancy
• Assess clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
• Evaluate emerging clinical trial data of current and novel BTK inhibitors, including monotherapy and combination approaches
• Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, as well as oral adherence strategies

Activity Description

Bruton’s tyrosine kinase (BTK) inhibitors are an evolving therapeutic strategy for the treatment of patients with CLL. With multiple BTK inhibitors (and combinations) under investigation and pending approval, clinicians need expert guidance to correctly use these agents safely and effectively for patients with CLL, and plan strategies for optimal integration of these novel agents into practice. This webcast will provide expert interpretation of emerging data and guidance regarding patient diagnosis, treatment, maintenance therapy, and sequencing of agents.

Statement of Educational Need

BTK inhibitors have substantially altered the management, clinical course, and outcome of patients with CLL. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Ibrutinib was the first orally available, nonselective and irreversible inhibitor of BTK approved for the treatment of patients with various B-cell malignancies. Newer and more selective BTK inhibitors are currently in clinical development, including acalabrutinib, which is currently US FDA approved for previously treated mantle cell lymphoma. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control.

Faculty

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical Center
Associate Director, Center for Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts

Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.

Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research to Practice, TG Therapeutics, Verastem, Inc.

Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

All disclosed conflicts of interest have been resolved by independent content review.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, BeiGene and Pharmacyclics.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com